目的 探讨复方丹参滴丸联合铝镁匹林治疗不稳定型心绞痛的临床疗效。方法 纳入2023年2月—2026年1月界首市人民医院收治的86例不稳定型心绞痛患者，按随机数字表法分为对照组和治疗组。对照组口服铝镁匹林片（Ⅱ），1片/次，1次/d，温水送服。在此基础上，治疗组口服复方丹参滴丸，10丸/次，3次/d。疗程为4周。比较两组临床疗效和硝酸甘油停减率，治疗前后心绞痛发作情况和心绞痛视觉模拟评分法（VAS）、医院焦虑抑郁量表（HADS）、西雅图心绞痛量表（SAQ）评分，以及凝血指标[D-二聚体（D-D）、纤维蛋白原（FIB）、活化部分凝血活酶时间（APTT）]、血小板与淋巴细胞比值（PLR）、全身炎症反应指数（SIRI）和血清超敏肌钙蛋白I（hs-cTnI）、N末端B型脑钠肽前体（NT-proBNP）水平。结果 治疗后，治疗组总有效率、硝酸甘油停减率（95.35%、83.72%）均高于对照组（79.07%、65.12%，P＜0.05）。治疗后，心绞痛发作频率与发作持续时间均少于同组治疗前（P＜0.05）；且治疗组心绞痛发作频率与发作持续时间少于对照组（P＜0.05）。治疗后，两组心绞痛VAS评分与HADS评分均低于同组治疗前，SAQ评分均高于同组治疗前（P＜0.05）；且治疗组心绞痛VAS、HADS和SAQ评分均优于对照组（P＜0.05）。治疗后，两组D-D与FIB均低于同组治疗前，两组APTT均长于同组治疗前（P＜0.05）；且治疗组凝血指标均优于对照组（P＜0.05）。治疗后，两组PLR、SIRI、hs-cTnI、NT-proBNP均降低（P＜0.05），且治疗组上述指标均低于对照组（P＜0.05）。结论 采用复方丹参滴丸联合铝镁匹林治疗不稳定型心绞痛患者，能提升治疗效果，有效抑制机体凝血活性、炎症激活及心肌受损，从而改善心绞痛发作，促进患者情绪及生活状态优化，且不增加不良反应风险。

Objective To explore the clinical efficacy of Compound Danshen Dripping Pills combined with aluminum magnesium aspirin in treatment of unstable angina pectoris. Methods A total of 86 patients with unstable angina pectoris admitted to Jieshou City People’s Hospital from February 2023 to January 2026 were enrolled and equally divided into a control group and a treatment group using the random number table method. Patients in the control group were given oral Aluminum Magnesium Aspirin Tablets (II), 1 tablet per dose, once daily, taken with warm water. On this basis, Patients in the treatment group received oral Compound Danshen Dripping Pills, 10 pills per dose, 3 times daily. The course of treatment was 4 weeks. The clinical efficacy and nitroglycerin withdrawal/reduction rate were compared between the two groups, as well as the angina attack status before and after treatment; scores on the Visual Analogue Scale (VAS) for angina, Hospital Anxiety and Depression Scale (HADS), and Seattle Angina Questionnaire (SAQ); coagulation indicators [D-dimer (D-D), fibrinogen (FIB), activated partial thromboplastin time (APTT)]; platelet-to-lymphocyte ratio (PLR); systemic inflammation response index (SIRI); and serum levels of high-sensitivity cardiac troponin I (hs-cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Results After treatment, the total effective rate and nitroglycerin withdrawal/reduction rate in the treatment group (95.35%, 83.72%) were higher than those in the control group (79.07%, 65.12%, P< 0.05). After treatment, the frequency and duration of angina attacks in both groups were lower and shorter than those before treatment in the same group (P < 0.05); moreover, the frequency and duration of angina attacks in the treatment group were lower and shorter than those in the control group (P < 0.05). After treatment, the angina VAS score and HADS score in both groups were lower than those before treatment in the same group (P < 0.05), while the SAQ score was higher than that before treatment in the same group (P < 0.05); the angina VAS, HADS, and SAQ scores in the treatment group were all better than those in the control group (P < 0.05). After treatment, D-D and FIB in both groups were lower than those before treatment in the same group (P< 0.05); APTT in both groups was longer than that before treatment in the same group (P < 0.05); and the coagulation indicators in the treatment group were better than those in the control group (P < 0.05). After treatment, PLR, SIRI, hs-cTnI, and NT-proBNP in both groups decreased (P < 0.05), and the above indicators in the treatment group were lower than those in the control group (P < 0.05). Conclusion Compound Danshen Dripping Pills combined with aluminum magnesium aspirin in treatment of unstable angina pectoris can enhance therapeutic efficacy, effectively inhibit the body's coagulation activity, inflammatory activation, and myocardial injury, thereby improving angina attacks and promoting the optimization of patients' emotional and living status, without increasing the risk of adverse reactions.

R972